164653-83-2

Basic information

• Product Name: 1,4-Butanediol, 2-phenyl-, dimethanesulfonate, (2S)-
• CAS NO: 164653-83-2
• Molecular Formula: C12H18O6S2
• Molecular Weight: 322.403
• Mol File: 164653-83-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1,4-Butanediol, 2-phenyl-, dimethanesulfonate, (2S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-Butanediol, 2-phenyl-, dimethanesulfonate, (2S)-(164653-83-2)
• EPA Substance Registry System: 1,4-Butanediol, 2-phenyl-, dimethanesulfonate, (2S)-(164653-83-2)

Safety Data

• Hazardous Substances Data: 164653-83-2(Hazardous Substances Data)

Upstream product

• 159528-25-3 (S)-di-tert-butyl-2-phenylsuccinate 
• 98-80-6 phenylboronic acid 
• 15463-92-0 (S)-(+)-dimethyl 2-phenylsuccinate 
• 4036-30-0 (S)-2-phenylsuccinic acid 
• 6837-05-4 (2S)-2-phenylbutane-1,4-diol 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 59349-74-5 (S)-N-benzyl-3-phenylpyrrolidine 
• 883901-38-0 (S)-3-(4-amino-phenyl)-1-propyl-pyrrolidine 
• 883901-37-9 (S)-3-(4-nitro-phenyl)-1-propyl-pyrrolidine 
• 883901-36-8 (S)-3-phenyl-1-propyl-pyrrolidine 

Relevant articles and documents

Preparation of chiral 3-arylpyrrolidines via the enantioselective 1,4-addition of arylboronic acids to fumaric esters catalyzed by Rh(I)/chiral diene complexes

A highly efficient rhodium-catalyzed protocol for the preparation of 2-arylsuccinic esters and 3-arylpyrrolidines of high optical purity has been achieved. In the presence of 1 mol % of a chiral diene/Rh(I) catalyst, asymmetric addition of various arylbor

HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR

The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH2 or CHR3; R1 is H, C,-C6-alkyl, C,-C6-alkyl substituted by C3-C6-cycloalkyl, Cl-C6-hydroxyalkyl, fluorinated C,-C6-alkyl, C3-C6-cycloalkyl, fluorinated C3-C6-cycloalkyl, C3-C6- alkenyl, fluorinated C3-C6-alkenyl, formyl, acetyl or propionyl; R2, R3 and R4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF3; E is NR5 or CH2, wherein R5 is H or C1 -C3-alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6- -membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR8, where R8 is H, C1-C4-alkyl, fluorinated C1-C4-alkyl, C1-C4-alkylcarbonyl or fluorinated C1-C4-alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents Ra, wherein the variable Ra has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.